SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as community discussion intensely focuses on reported US-Israel strikes in Iran, including the death of Ayatollah Ali Khamenei, with supporters praising it as a decisive geopolitical action and critics condemning it as dangerous escalation and a potential distraction from ongoing domestic controversies.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevron is actively discussed among investors as escalating Middle East tensions, including reports of US/Israel strikes on Iran and threats to the Strait of Hormuz, are sparking widespread speculation about a significant surge in oil prices and potential supply disruptions.

Agnico Eagle Mines Ltd. engages in the exploration and production of gold. It operates through the following segments: Northern Business, Southern Business, and Exploration. The Northern Business segment comprises of LaRonde mine, LaRonde Zone 5 mine, Lapa mine, Goldex mine, Meadowbank mine including the Amaruq deposit, Canadian Malartic joint operation, Meliadine project and Kittila mine. The Southern Business segment consists of Pinos Altos mine, Creston Mascota mine, and La India mine. The Exploration segment represents the exploration offices in the United States, Europe, Canada, and Latin America. The company was founded by Paul Penna in 1957 and is headquartered in Toronto, Canada.

Agnico Eagle Mines Ltd

Agnico Eagle Mines is a major discussion point after repeatedly delivering strong earnings and significant free cash flow, fueled by a sustained rally in gold prices and strategic balance sheet improvements; the community sees it as a top-tier gold miner positioned for continued strength in the current market.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending after announcing a multi-year AI inference collaboration with SambaNova, alongside community discussions intensifying around a significant Nvidia investment and speculation of foundry deals, collectively fueling optimism for Intel's domestic chip manufacturing turnaround.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. It focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is trending amidst a broad financial sector selloff driven by credit concerns, fueling debate between bullish dip-buyers and bearish investors noting significant put option activity and CEO Jamie Dimon's warnings about the private credit market.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is trending as the community debates its long-term viability following recent institutional benchmarks on Coinbase and its mainnet launch; bulls cite these developments as validation for continued accumulation, while skeptics decry it as a "pump and dump" project with persistent underperformance.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

Heightened speculation surrounding a potential acquisition, particularly from major pharmaceutical players, is driving conversation around CRISPR Therapeutics. The community is also closely watching for further updates on Casgevy's market performance and the company's gene-editing pipeline, which is seen as benefiting from a supportive regulatory landscape for innovative therapies.

Constellation Energy Corp. engages in the generation, supply, and marketing of clean electricity, and renewable energy products and solutions. The firm also offers wholesale energy, retail products and services. It operates under the following geographical segments: Mid-Atlantic, Midwest, New York, Electric Reliability Council of Texas (ERCOT), and Other Power Regions Segment. The company was founded in 1960 and is headquartered in Baltimore, MD.

Constellation Energy Corporation

Constellation Energy Corp

Constellation Energy (CEG) is trending following robust Q4 earnings, a dividend increase, and its newly solidified position as the largest U.S. power producer after the Calpine acquisition. Community discussion highlights CEG's critical role in powering the massive demands of AI data centers, a narrative driving bullish sentiment despite recent market volatility surrounding regulatory discussions on electricity pricing.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

General Motors is trending after a strong Q4 earnings report, featuring a raised dividend and a new stock buyback program, fueling investor confidence; simultaneously, the company's significant EV-related charges and strategic scaling back of some electrification plans are drawing community discussion as a pivot towards sustainable profitability.

ProShares Trust - ProShares Ultra VIX Short-Term Futures ETF 1.5x Shares

ProShares Ultra VIX Short-Term Futures ETF

UVXY is trending amidst heightened geopolitical uncertainty, particularly concerning potential Middle East conflicts, and varied economic data points. The community is sharply divided between those anticipating significant volatility spikes and others actively shorting, expecting the ETF's typical decay if markets remain calm.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (Satellos or the Company), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today...

Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy

Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (Satellos or the Company), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today...

Satellos to Participate in Upcoming Investor Conferences

Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (Satellos or the Company), a clinical-stage biotechnology company focused on restoring natural muscle repair and regeneration in degenerative muscle...

<ul class="summary-bullets"><li>MSLE stock&nbsp;was down about 2%&nbsp;in overnight trading heading into Tuesday.</li><li>The company completed a $57.2 million public offering to fund its lead drug, SAT-3247, and other research into muscle diseases.</li><li>Early data for SAT-3247 is expected in the second quarter of 2026, following encouraging adult safety results.</li></ul>Shares of Satellos Bioscience Inc. (MSLE) opened more than 10% above their offering price in the company’s Nasdaq debut on Monday before ending the session more than 3% lower and dipping over 8% in after-hours trading.Investor sentiment took a hit after the company revealed it had completed an equity raise to fund its Duchenne muscular dystrophy (DMD) program and broader muscle disease research.&nbsp;<h2 class="st-heading-2">MSLE Wraps Up Equity Raise</h2>Satellos said it has completed its underwritten public offering, raising about $57.2 million before fees. The deal included roughly 5.2 million common shares, along with pre-funded warrants for some investors. The <a href="https://stocktwits.com/symbol/MSLE">shares of Satellos</a> were sold at $10.1 each. The stock is also listed on the Toronto Stock Exchange under the MSCL ticker.The company said the funds will mainly support research and development, with a focus on advancing SAT-3247, its lead drug candidate, into mid and late-stage clinical trials. Some of the money will also be used to explore additional muscle-related diseases and support early-stage research programs.Ahead of the Nasdaq listing, Satellos carried out a 1-for-12 share consolidation in late January. This reduced the total number of shares from about 185.5 million to roughly 15.5 million, helping the stock meet Nasdaq’s listing requirements.<h2 class="st-heading-2">How SAT-3247 Works</h2>SAT-3247 is an oral drug designed to help the body repair and regenerate muscle by targeting a protein called AAK1, which plays a role in muscle stem cell signaling. Unlike gene therapies, SAT-3247 does not depend on fixing the dystrophin gene, meaning it could potentially work for a wide range of Duchenne patients, regardless of their specific genetic mutation.In December, Satellos received FDA clearance and approvals from global regulators to begin a Phase 2 clinical study of SAT-3247 in 51 children with Duchenne. The study will test safety and measure changes in muscle strength and function. The company expects early trial results in the second quarter of 2026. Earlier studies in adults showed that the drug was well tolerated and associated with improvements in grip strength over a 28-day treatment period.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for Satellos Bioscience was ‘neutral’ amid ‘extremely low’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/msle_ss_png_8d0bdc8b59.webp" alt="msle ss.png" width="973" height="142"><figcaption>MSLE sentiment and message volume as of February 10 | Source: Stocktwits</figcaption></figure>One user said the company’s “Clinical results should be pretty stellar.”<stembedurl>https://stocktwits.com/bruceleeboy/message/644522213</stembedurl>Another user said, “It looks like all went well with the listing. Great work. Let’s see if we&nbsp; get something going this Spring.”<stembedurl>https://stocktwits.com/PennyScam/message/644421647</stembedurl>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Shares of Satellos Bioscience Inc. (MSLE) opened more than 10% above their offering price in the company’s Nasdaq debut on Monday. (Photo credit: Getty Images)

Why MSLE Stock Gave Up All Nasdaq Debut Gains And Fell 8% After Hours

SAT-3247, an oral therapy aimed at restoring muscle repair, is now in Phase 2 testing in children with DMD.

Equity

Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters Option to Purchase Additional Shares

Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States

Satellos Bioscience Inc. (TSX: MSCL, Nasdaq: MSLE) (Satellos or the Company), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today...

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki on July 27, 2012 and is headquartered in Toronto, Canada.

Satellos Bioscience Inc

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

MSLE
Satellos Bioscience Inc

Feed

News

Sentiment

Fundamentals

Info

Latest MSLE News

MSLESatellos Bioscience Inc